HB-101 is a prophylactic Vaxwave® based vaccine against Cytomegalovirus (CMV) infection. It delivers two clinically proven antigens, glycoprotein B (gB) to elicit CMV-neutralizing antibodies, and pp65, to induce CMV-specific cytotoxic T cells.
A majority of the global human population, ranging from 30 – 97% depending on the region, is latently infected with CMV, and can transmit the infection by bodily fluids. While infections in immunocompetent individuals are typically mild or even asymptomatic, CMV is an important cause of morbidity and mortality in individuals with compromised immune defense: Transmission from pregnant women to their fetuses can result in severe malformation and death of the unborn child. CMV is also a life-threatening infection for solid organ and hematopoietic stem cell transplant recipients. According to the Center for Disease Control (CDC) in the US, about 1 out of every 200 babies in developed countries such as the United States is born with congenital CMV and 1 out of 5 of these babies will have birth defects or other long-term health problems. In a CMV negative patient receiving an organ or stem cells from a CMV positive donor, viremic dissemination can cause end-organ disease, such as hepatitis, pneumonitis, gastroenteritis , and retinitis, and can predispose to transplant rejection and even death. Anti-viral prophylactic strategies have limited efficacy as well as certain toxicities, drug-drug interactions, and development of anti-viral resistance.
The objective of the Hepatitis B (HBV) Program is to utilize the Hookipa Technologies to design arenavirus vectors (Lymphocytic Choriomeningitis Virus or Pichinde Virus based) suitable for treatment, cure or prevention of HBV. Together with our partner Gilead Sciences we intend to develop functional therapies for patients already infected with the HB Virus.
An estimated 257 million people are living with HBV infection (defined as hepatitis B surface antigen positive). In 2015, HBV resulted in 887,000 deaths, mostly from complications including cirrhosis and hepatocellular carcinoma1. HBV virus is especially common in China and other Asian countries where infant immunization for the disease is not yet routine. HBV is second only to tobacco as a cancer-causing agent.
Human Immunodeficiency Virus
The objective of the Human Immunodeficiency Virus (HIV) program is to use Hookipa’s technologies to design arenavirus vectors (Lymphocytic Choriomeningitis Virus or Pichinde Virus based) suitable for treatment, cure or prevention of HIV. Together with our partner Gilead Sciences we intend to develop functional therapies for patients already infected with the HIV.
Today, HIV continues to be a major global public health issue, having claimed more than 35 million lives so far and affecting approximately 36.9 million people at the end of 2017 . HIV research has come a long way since the discovery of the disease in the 1980’s but there is no cure for HIV infection. There are antiretroviral (ARV) drugs that control the virus and help prevent transmission. The goal now is to find a cure for HIV to change the lives of millions affected by the disease.